OIPE					•	
SC)	<b>4</b>					
APR 2 8 2003	95. no persons are required	U.S. Patent and d to respond to a collection of i	Trademark Of	r use through 10/31/20 fice; U.S. DEPARTMEI ess it contains a valid C	NT OF COMMERCE	
S. P. C. S.					631020.90015	
DECLARATION FO			First Named Inventor			
DESIGN PATENT APPLICATION (37 CFR 1.63)			COMPLETE IF KNOWN			
		Application Numb	oer 09	09 / 945,131		
	Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)	Filing Date	Augu	August 31, 2001		
Declaration Submitted OR with Initial Filing		al Group Art Unit	1635	1635		
		Examiner Name		<i>₹</i> o		
As a below named inventor, I he	reby declare that:					
My residence, mailing address, an		ed below next to my name.			With the	
I believe I am the original, first and	sole inventor (if only on	e name is listed below) or	an original, fi	rst and joint inventor	r (if plural	
names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:						
LOCALIZED OLIGONUCLEOTIDE THERAPY FOR PREVENTING RESTENOSIS						
	(Title of ti	he Invention)	···			
the specification of which	·	·				
is attached hereto						
OR						
was filed on (MM/DD/YYYY)	August 31, 2001	as United Stat	tes Applicatio	n Number or PCT In	iternational	
					,	
Application Number 09/945,13	1 and was a	amended on (MM/DD/YYY)	Y) n/a		(if applicable).	
I hereby state that I have reviewed amended by any amendment spec	I and understand the cor cifically referred to above	ntents of the above identifice.	ed specificati	on, including the cla	ims, as	
I acknowledge the duty to disclose in-part applications, material inform PCT international filing date of the	nation which became av	ailable between the filing d	efined in 37 C date of the pr	CFR 1.56, including fior application and the	or continuation- ne national or	
I hereby claim foreign priority ben- or plant breeder's rights certificat than the United States of Americ patent, inventor's or plant breeder application on which priority is clai	efits under 35 U.S.C. 11 e(s), or 365(a) of any P a, listed below and hav r's rights certificate(s), o	19(a)-(d) or (f), or 365(b) of PCT international applications of also identified below, b	on which des ov checkina t	signated at least on: he box, anv foreign	e country other application for	
Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed		py Attached? NO	
n/a						
			$\equiv$			

[Page 1 of 2]

Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

[Page 2 of 2]

I hereby certify that this correspondence is being deposited with the United States Postal Services on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Date of Signature and Deposit:

Attorney of Record

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Martin G. Sirois, et al.

Serial No.:

09/241,561

Filed:

February 1, 1999

For:

LOCALIZED OLIGONUCLEOTIDES THERAPY

FOR PREVENTING RESTENOSIS

Group Art Unit:

1635

Examiner:

A. Wang

## DECLARATION UNDER 37 CFR 1.132

APR 3 0 20

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

- 1. Martin G. Sirois, Michael Simons and Elazer R. Edelman are three of the named inventors in the above-identified patent application and are also the authors of Sirois, et al., Circulation 95(3) (February 4, 1997).
- 2. Inventor Robert D. Rosenberg was not an author on the Sirois, et al. paper because he did not contribute to the drafting of that paper. However, Inventor Rosenberg contributed to the idea that is presented in the paper and in the specification, and that is claimed in the above-referenced application.
- 3. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like made are punishable by fine or imprisonment, or both, under

Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the above-identified application or any patent issuing thereon.

Respectfully submitted,

14ml J 2001

Date